Stock Analysis on Net

Zoetis Inc. (NYSE:ZTS)

This company has been moved to the archive! The financial data has not been updated since May 2, 2024.

Analysis of Solvency Ratios 
Quarterly Data

Microsoft Excel

Solvency Ratios (Summary)

Zoetis Inc., solvency ratios (quarterly data)

Microsoft Excel
Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Debt Ratios
Debt to equity 1.30 1.31 1.29 1.42 1.46 1.79 1.41 1.44 1.41 1.45 1.41 1.65 1.76 1.91 2.14 2.58 2.35 2.38 2.41 2.67 2.78
Debt to equity (including operating lease liability) 1.34 1.35 1.33 1.46 1.50 1.84 1.45 1.47 1.45 1.48 1.44 1.69 1.80 1.95 2.18 2.63 2.41 2.44 2.47 2.74 2.84
Debt to capital 0.57 0.57 0.56 0.59 0.59 0.64 0.58 0.59 0.59 0.59 0.58 0.62 0.64 0.66 0.68 0.72 0.70 0.70 0.71 0.73 0.74
Debt to capital (including operating lease liability) 0.57 0.57 0.57 0.59 0.60 0.65 0.59 0.60 0.59 0.60 0.59 0.63 0.64 0.66 0.69 0.72 0.71 0.71 0.71 0.73 0.74
Debt to assets 0.46 0.46 0.46 0.48 0.48 0.53 0.48 0.48 0.47 0.47 0.48 0.51 0.52 0.53 0.56 0.59 0.56 0.56 0.57 0.59 0.59
Debt to assets (including operating lease liability) 0.47 0.47 0.48 0.49 0.49 0.54 0.49 0.49 0.49 0.49 0.49 0.52 0.53 0.54 0.57 0.60 0.57 0.57 0.59 0.60 0.60
Financial leverage 2.84 2.86 2.78 2.97 3.06 3.39 2.93 3.01 2.98 3.06 2.93 3.23 3.37 3.61 3.81 4.38 4.19 4.26 4.21 4.56 4.70
Coverage Ratios
Interest coverage 13.76 13.28 12.89 12.98 12.37 13.02 13.07 12.86 12.49 12.11 11.54 11.00 10.30 9.64 9.79 9.72 9.71 9.08

Based on: 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

Solvency ratio Description The company
Debt to equity ratio A solvency ratio calculated as total debt divided by total shareholders’ equity. Zoetis Inc. debt to equity ratio deteriorated from Q3 2023 to Q4 2023 but then improved from Q4 2023 to Q1 2024 not reaching Q3 2023 level.
Debt to equity (including operating lease liability) ratio A solvency ratio calculated as total debt (including operating lease liability) divided by total shareholders’ equity. Zoetis Inc. debt to equity ratio (including operating lease liability) deteriorated from Q3 2023 to Q4 2023 but then improved from Q4 2023 to Q1 2024 not reaching Q3 2023 level.
Debt to capital ratio A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. Zoetis Inc. debt to capital ratio deteriorated from Q3 2023 to Q4 2023 but then improved from Q4 2023 to Q1 2024 not reaching Q3 2023 level.
Debt to capital (including operating lease liability) ratio A solvency ratio calculated as total debt (including operating lease liability) divided by total debt (including operating lease liability) plus shareholders’ equity. Zoetis Inc. debt to capital ratio (including operating lease liability) deteriorated from Q3 2023 to Q4 2023 but then improved from Q4 2023 to Q1 2024 not reaching Q3 2023 level.
Debt to assets ratio A solvency ratio calculated as total debt divided by total assets. Zoetis Inc. debt to assets ratio improved from Q3 2023 to Q4 2023 and from Q4 2023 to Q1 2024.
Debt to assets (including operating lease liability) ratio A solvency ratio calculated as total debt (including operating lease liability) divided by total assets. Zoetis Inc. debt to assets ratio (including operating lease liability) improved from Q3 2023 to Q4 2023 and from Q4 2023 to Q1 2024.
Financial leverage ratio A solvency ratio calculated as total assets divided by total shareholders’ equity. Zoetis Inc. financial leverage ratio increased from Q3 2023 to Q4 2023 but then slightly decreased from Q4 2023 to Q1 2024.

Solvency ratio Description The company
Interest coverage ratio A solvency ratio calculated as EBIT divided by interest payments. Zoetis Inc. interest coverage ratio improved from Q3 2023 to Q4 2023 and from Q4 2023 to Q1 2024.

Debt to Equity

Zoetis Inc., debt to equity calculation (quarterly data)

Microsoft Excel
Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Selected Financial Data (US$ in millions)
Short-term borrowings 24 3 2 2 3 2 3 2 4 4 4 1 1
Current portion of long-term debt 1,350 1,350 1,350 1,350 600 600 600 1,100 500 500 500
Long-term debt, net of discount and issuance costs, excluding current portion 6,562 6,564 6,552 6,555 6,559 6,552 5,210 5,221 5,228 6,592 6,592 6,592 6,587 6,595 6,595 7,194 5,963 5,947 6,447 6,446 6,444
Total debt 6,586 6,567 6,554 6,557 6,562 7,904 6,563 6,573 6,578 6,592 6,592 7,196 7,191 7,199 7,696 7,695 6,463 6,447 6,447 6,446 6,444
 
Total Zoetis Inc. equity 5,058 4,997 5,078 4,625 4,494 4,405 4,663 4,580 4,658 4,543 4,679 4,350 4,089 3,769 3,602 2,982 2,753 2,708 2,678 2,411 2,317
Solvency Ratio
Debt to equity1 1.30 1.31 1.29 1.42 1.46 1.79 1.41 1.44 1.41 1.45 1.41 1.65 1.76 1.91 2.14 2.58 2.35 2.38 2.41 2.67 2.78
Benchmarks
Debt to Equity, Competitors2
AbbVie Inc. 9.24 5.73 5.02 4.74 4.68 3.67 4.35 4.98 4.51 4.98 5.96 6.53 6.24 6.58 5.70 5.94
Amgen Inc. 12.75 10.37 7.90 9.08 11.52 10.64 10.60 15.10 40.23 4.97 4.57 3.98 3.50 3.51 3.13 3.21 3.36 3.09 2.73 2.84 3.05
Bristol-Myers Squibb Co. 3.38 1.35 1.30 1.18 1.19 1.27 1.20 1.29 1.42 1.24 1.20 1.23 1.23 1.34 0.90 0.95 0.94 0.91 1.41 1.56 0.40
Danaher Corp. 0.34 0.34 0.42 0.38 0.39 0.39 0.41 0.43 0.47 0.49 0.54 0.48 0.50 0.53 0.57 0.62 0.84 0.72 0.54 0.32 0.30
Eli Lilly & Co. 2.05 2.34 1.80 1.70 1.69 1.52 1.58 1.97 1.77 1.88 2.20 2.56 2.35 2.94 3.51 3.99 5.60 5.88 4.50 5.68 6.44
Gilead Sciences Inc. 1.44 1.09 1.12 1.19 1.20 1.19 1.20 1.30 1.32 1.27 1.29 1.53 1.59 1.73 1.68 1.34 1.09 1.09 1.19 1.15 1.21
Johnson & Johnson 0.48 0.43 0.42 0.61 0.75 0.52 0.43 0.43 0.44 0.46 0.48 0.48 0.51 0.56 0.59 0.48 0.45 0.47 0.50 0.48 0.50
Merck & Co. Inc. 0.85 0.93 0.85 0.95 0.66 0.67 0.68 0.73 0.78 0.87 0.74 0.80 1.16 1.26 0.98 1.12 1.07 1.02 0.97 0.96 0.94
Moderna Inc. 0.04 0.04 0.04 0.05 0.04 0.05 0.05 0.04 0.04 0.04 0.02 0.05 0.04 0.04 0.04 0.02 0.02 0.03 0.04 0.03 0.03
Pfizer Inc. 0.75 0.81 0.66 0.66 0.36 0.37 0.40 0.46 0.44 0.50 0.53 0.56 0.58 0.63 0.97 0.99 0.80 0.83 0.81 0.78 0.77
Regeneron Pharmaceuticals Inc. 0.10 0.10 0.11 0.11 0.11 0.12 0.13 0.13 0.14 0.14 0.16 0.18 0.23 0.24 0.27 0.24 0.06 0.06 0.07 0.07 0.08
Thermo Fisher Scientific Inc. 0.78 0.75 0.78 0.78 0.83 0.78 0.67 0.72 0.81 0.85 0.56 0.51 0.53 0.63 0.66 0.71 0.70 0.60 0.58 0.66 0.66

Based on: 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

1 Q1 2024 Calculation
Debt to equity = Total debt ÷ Total Zoetis Inc. equity
= 6,586 ÷ 5,058 = 1.30

2 Click competitor name to see calculations.

Solvency ratio Description The company
Debt to equity ratio A solvency ratio calculated as total debt divided by total shareholders’ equity. Zoetis Inc. debt to equity ratio deteriorated from Q3 2023 to Q4 2023 but then improved from Q4 2023 to Q1 2024 not reaching Q3 2023 level.

Debt to Equity (including Operating Lease Liability)

Zoetis Inc., debt to equity (including operating lease liability) calculation (quarterly data)

Microsoft Excel
Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Selected Financial Data (US$ in millions)
Short-term borrowings 24 3 2 2 3 2 3 2 4 4 4 1 1
Current portion of long-term debt 1,350 1,350 1,350 1,350 600 600 600 1,100 500 500 500
Long-term debt, net of discount and issuance costs, excluding current portion 6,562 6,564 6,552 6,555 6,559 6,552 5,210 5,221 5,228 6,592 6,592 6,592 6,587 6,595 6,595 7,194 5,963 5,947 6,447 6,446 6,444
Total debt 6,586 6,567 6,554 6,557 6,562 7,904 6,563 6,573 6,578 6,592 6,592 7,196 7,191 7,199 7,696 7,695 6,463 6,447 6,447 6,446 6,444
Noncurrent operating lease liabilities 184 188 191 188 180 186 186 161 158 151 160 147 159 163 167 155 159 164 169 169 134
Total debt (including operating lease liability) 6,770 6,755 6,745 6,745 6,742 8,090 6,749 6,734 6,736 6,743 6,752 7,343 7,350 7,362 7,863 7,850 6,622 6,611 6,616 6,615 6,578
 
Total Zoetis Inc. equity 5,058 4,997 5,078 4,625 4,494 4,405 4,663 4,580 4,658 4,543 4,679 4,350 4,089 3,769 3,602 2,982 2,753 2,708 2,678 2,411 2,317
Solvency Ratio
Debt to equity (including operating lease liability)1 1.34 1.35 1.33 1.46 1.50 1.84 1.45 1.47 1.45 1.48 1.44 1.69 1.80 1.95 2.18 2.63 2.41 2.44 2.47 2.74 2.84
Benchmarks
Debt to Equity (including Operating Lease Liability), Competitors2
Moderna Inc. 0.09 0.09 0.09 0.06 0.05 0.05 0.06 0.04 0.04 0.05 0.03 0.06 0.06 0.08 0.08 0.06 0.09 0.11 0.04 0.03 0.03

Based on: 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

1 Q1 2024 Calculation
Debt to equity (including operating lease liability) = Total debt (including operating lease liability) ÷ Total Zoetis Inc. equity
= 6,770 ÷ 5,058 = 1.34

2 Click competitor name to see calculations.

Solvency ratio Description The company
Debt to equity (including operating lease liability) ratio A solvency ratio calculated as total debt (including operating lease liability) divided by total shareholders’ equity. Zoetis Inc. debt to equity ratio (including operating lease liability) deteriorated from Q3 2023 to Q4 2023 but then improved from Q4 2023 to Q1 2024 not reaching Q3 2023 level.

Debt to Capital

Zoetis Inc., debt to capital calculation (quarterly data)

Microsoft Excel
Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Selected Financial Data (US$ in millions)
Short-term borrowings 24 3 2 2 3 2 3 2 4 4 4 1 1
Current portion of long-term debt 1,350 1,350 1,350 1,350 600 600 600 1,100 500 500 500
Long-term debt, net of discount and issuance costs, excluding current portion 6,562 6,564 6,552 6,555 6,559 6,552 5,210 5,221 5,228 6,592 6,592 6,592 6,587 6,595 6,595 7,194 5,963 5,947 6,447 6,446 6,444
Total debt 6,586 6,567 6,554 6,557 6,562 7,904 6,563 6,573 6,578 6,592 6,592 7,196 7,191 7,199 7,696 7,695 6,463 6,447 6,447 6,446 6,444
Total Zoetis Inc. equity 5,058 4,997 5,078 4,625 4,494 4,405 4,663 4,580 4,658 4,543 4,679 4,350 4,089 3,769 3,602 2,982 2,753 2,708 2,678 2,411 2,317
Total capital 11,644 11,564 11,632 11,182 11,056 12,309 11,226 11,153 11,236 11,135 11,271 11,546 11,280 10,968 11,298 10,677 9,216 9,155 9,125 8,857 8,761
Solvency Ratio
Debt to capital1 0.57 0.57 0.56 0.59 0.59 0.64 0.58 0.59 0.59 0.59 0.58 0.62 0.64 0.66 0.68 0.72 0.70 0.70 0.71 0.73 0.74
Benchmarks
Debt to Capital, Competitors2
AbbVie Inc. 0.90 0.85 0.83 0.83 0.82 0.79 0.81 0.83 0.82 0.83 0.86 0.87 0.86 0.87 0.85 0.86 1.12 1.14 1.27 1.30 1.27
Amgen Inc. 0.93 0.91 0.89 0.90 0.92 0.91 0.91 0.94 0.98 0.83 0.82 0.80 0.78 0.78 0.76 0.76 0.77 0.76 0.73 0.74 0.75
Bristol-Myers Squibb Co. 0.77 0.57 0.56 0.54 0.54 0.56 0.54 0.56 0.59 0.55 0.55 0.55 0.55 0.57 0.47 0.49 0.48 0.48 0.59 0.61 0.28
Danaher Corp. 0.25 0.26 0.30 0.28 0.28 0.28 0.29 0.30 0.32 0.33 0.35 0.32 0.33 0.35 0.37 0.38 0.46 0.42 0.35 0.24 0.23
Eli Lilly & Co. 0.67 0.70 0.64 0.63 0.63 0.60 0.61 0.66 0.64 0.65 0.69 0.72 0.70 0.75 0.78 0.80 0.85 0.85 0.82 0.85 0.87
Gilead Sciences Inc. 0.59 0.52 0.53 0.54 0.55 0.54 0.54 0.56 0.57 0.56 0.56 0.60 0.61 0.63 0.63 0.57 0.52 0.52 0.54 0.54 0.55
Johnson & Johnson 0.32 0.30 0.30 0.38 0.43 0.34 0.30 0.30 0.31 0.31 0.33 0.32 0.34 0.36 0.37 0.33 0.31 0.32 0.33 0.33 0.33
Merck & Co. Inc. 0.46 0.48 0.46 0.49 0.40 0.40 0.41 0.42 0.44 0.46 0.42 0.44 0.54 0.56 0.50 0.53 0.52 0.50 0.49 0.49 0.48
Moderna Inc. 0.04 0.04 0.04 0.05 0.04 0.05 0.05 0.03 0.04 0.04 0.02 0.05 0.03 0.04 0.04 0.02 0.02 0.03 0.04 0.03 0.03
Pfizer Inc. 0.43 0.45 0.40 0.40 0.26 0.27 0.28 0.32 0.31 0.33 0.35 0.36 0.37 0.39 0.49 0.50 0.45 0.45 0.45 0.44 0.43
Regeneron Pharmaceuticals Inc. 0.09 0.09 0.10 0.10 0.10 0.11 0.11 0.12 0.12 0.13 0.14 0.15 0.18 0.20 0.21 0.20 0.06 0.06 0.06 0.07 0.07
Thermo Fisher Scientific Inc. 0.44 0.43 0.44 0.44 0.45 0.44 0.40 0.42 0.45 0.46 0.36 0.34 0.35 0.39 0.40 0.42 0.41 0.37 0.37 0.40 0.40

Based on: 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

1 Q1 2024 Calculation
Debt to capital = Total debt ÷ Total capital
= 6,586 ÷ 11,644 = 0.57

2 Click competitor name to see calculations.

Solvency ratio Description The company
Debt to capital ratio A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. Zoetis Inc. debt to capital ratio deteriorated from Q3 2023 to Q4 2023 but then improved from Q4 2023 to Q1 2024 not reaching Q3 2023 level.

Debt to Capital (including Operating Lease Liability)

Zoetis Inc., debt to capital (including operating lease liability) calculation (quarterly data)

Microsoft Excel
Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Selected Financial Data (US$ in millions)
Short-term borrowings 24 3 2 2 3 2 3 2 4 4 4 1 1
Current portion of long-term debt 1,350 1,350 1,350 1,350 600 600 600 1,100 500 500 500
Long-term debt, net of discount and issuance costs, excluding current portion 6,562 6,564 6,552 6,555 6,559 6,552 5,210 5,221 5,228 6,592 6,592 6,592 6,587 6,595 6,595 7,194 5,963 5,947 6,447 6,446 6,444
Total debt 6,586 6,567 6,554 6,557 6,562 7,904 6,563 6,573 6,578 6,592 6,592 7,196 7,191 7,199 7,696 7,695 6,463 6,447 6,447 6,446 6,444
Noncurrent operating lease liabilities 184 188 191 188 180 186 186 161 158 151 160 147 159 163 167 155 159 164 169 169 134
Total debt (including operating lease liability) 6,770 6,755 6,745 6,745 6,742 8,090 6,749 6,734 6,736 6,743 6,752 7,343 7,350 7,362 7,863 7,850 6,622 6,611 6,616 6,615 6,578
Total Zoetis Inc. equity 5,058 4,997 5,078 4,625 4,494 4,405 4,663 4,580 4,658 4,543 4,679 4,350 4,089 3,769 3,602 2,982 2,753 2,708 2,678 2,411 2,317
Total capital (including operating lease liability) 11,828 11,752 11,823 11,370 11,236 12,495 11,412 11,314 11,394 11,286 11,431 11,693 11,439 11,131 11,465 10,832 9,375 9,319 9,294 9,026 8,895
Solvency Ratio
Debt to capital (including operating lease liability)1 0.57 0.57 0.57 0.59 0.60 0.65 0.59 0.60 0.59 0.60 0.59 0.63 0.64 0.66 0.69 0.72 0.71 0.71 0.71 0.73 0.74
Benchmarks
Debt to Capital (including Operating Lease Liability), Competitors2
Moderna Inc. 0.09 0.08 0.09 0.05 0.05 0.05 0.05 0.04 0.04 0.05 0.03 0.06 0.06 0.07 0.07 0.05 0.08 0.10 0.04 0.03 0.03

Based on: 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

1 Q1 2024 Calculation
Debt to capital (including operating lease liability) = Total debt (including operating lease liability) ÷ Total capital (including operating lease liability)
= 6,770 ÷ 11,828 = 0.57

2 Click competitor name to see calculations.

Solvency ratio Description The company
Debt to capital (including operating lease liability) ratio A solvency ratio calculated as total debt (including operating lease liability) divided by total debt (including operating lease liability) plus shareholders’ equity. Zoetis Inc. debt to capital ratio (including operating lease liability) deteriorated from Q3 2023 to Q4 2023 but then improved from Q4 2023 to Q1 2024 not reaching Q3 2023 level.

Debt to Assets

Zoetis Inc., debt to assets calculation (quarterly data)

Microsoft Excel
Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Selected Financial Data (US$ in millions)
Short-term borrowings 24 3 2 2 3 2 3 2 4 4 4 1 1
Current portion of long-term debt 1,350 1,350 1,350 1,350 600 600 600 1,100 500 500 500
Long-term debt, net of discount and issuance costs, excluding current portion 6,562 6,564 6,552 6,555 6,559 6,552 5,210 5,221 5,228 6,592 6,592 6,592 6,587 6,595 6,595 7,194 5,963 5,947 6,447 6,446 6,444
Total debt 6,586 6,567 6,554 6,557 6,562 7,904 6,563 6,573 6,578 6,592 6,592 7,196 7,191 7,199 7,696 7,695 6,463 6,447 6,447 6,446 6,444
 
Total assets 14,348 14,286 14,106 13,749 13,754 14,925 13,674 13,770 13,860 13,900 13,705 14,069 13,796 13,609 13,725 13,069 11,528 11,545 11,272 10,986 10,883
Solvency Ratio
Debt to assets1 0.46 0.46 0.46 0.48 0.48 0.53 0.48 0.48 0.47 0.47 0.48 0.51 0.52 0.53 0.56 0.59 0.56 0.56 0.57 0.59 0.59
Benchmarks
Debt to Assets, Competitors2
AbbVie Inc. 0.50 0.44 0.45 0.45 0.46 0.46 0.49 0.51 0.51 0.52 0.54 0.56 0.57 0.57 0.58 0.58 0.74 0.75 0.65 0.65 0.65
Amgen Inc. 0.69 0.67 0.67 0.68 0.69 0.60 0.61 0.62 0.62 0.54 0.58 0.55 0.52 0.52 0.53 0.53 0.52 0.50 0.50 0.52 0.52
Bristol-Myers Squibb Co. 0.56 0.42 0.41 0.40 0.40 0.41 0.40 0.42 0.44 0.41 0.40 0.41 0.41 0.43 0.36 0.36 0.36 0.36 0.43 0.45 0.17
Danaher Corp. 0.22 0.22 0.25 0.23 0.23 0.23 0.24 0.25 0.26 0.27 0.29 0.26 0.27 0.28 0.30 0.31 0.38 0.35 0.29 0.19 0.18
Eli Lilly & Co. 0.41 0.39 0.35 0.34 0.36 0.33 0.33 0.36 0.35 0.35 0.35 0.35 0.35 0.36 0.39 0.39 0.42 0.39 0.40 0.41 0.42
Gilead Sciences Inc. 0.45 0.40 0.40 0.40 0.41 0.40 0.40 0.42 0.42 0.39 0.41 0.44 0.45 0.46 0.48 0.43 0.40 0.40 0.42 0.41 0.42
Johnson & Johnson 0.20 0.18 0.18 0.24 0.27 0.21 0.18 0.18 0.19 0.19 0.19 0.19 0.19 0.20 0.22 0.19 0.18 0.18 0.19 0.19 0.20
Merck & Co. Inc. 0.32 0.33 0.33 0.35 0.29 0.28 0.28 0.30 0.30 0.31 0.28 0.29 0.34 0.35 0.32 0.34 0.33 0.31 0.31 0.32 0.31
Moderna Inc. 0.03 0.03 0.03 0.04 0.03 0.04 0.04 0.02 0.02 0.02 0.01 0.02 0.01 0.01 0.02 0.02 0.02 0.02 0.03 0.03 0.02
Pfizer Inc. 0.31 0.32 0.30 0.30 0.18 0.18 0.19 0.21 0.20 0.21 0.22 0.23 0.25 0.26 0.35 0.36 0.31 0.31 0.31 0.30 0.29
Regeneron Pharmaceuticals Inc. 0.08 0.08 0.08 0.09 0.09 0.09 0.10 0.10 0.10 0.11 0.11 0.13 0.15 0.16 0.17 0.15 0.05 0.05 0.05 0.05 0.06
Thermo Fisher Scientific Inc. 0.37 0.35 0.36 0.36 0.37 0.35 0.32 0.33 0.36 0.37 0.29 0.28 0.28 0.31 0.33 0.35 0.34 0.30 0.30 0.33 0.33

Based on: 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

1 Q1 2024 Calculation
Debt to assets = Total debt ÷ Total assets
= 6,586 ÷ 14,348 = 0.46

2 Click competitor name to see calculations.

Solvency ratio Description The company
Debt to assets ratio A solvency ratio calculated as total debt divided by total assets. Zoetis Inc. debt to assets ratio improved from Q3 2023 to Q4 2023 and from Q4 2023 to Q1 2024.

Debt to Assets (including Operating Lease Liability)

Zoetis Inc., debt to assets (including operating lease liability) calculation (quarterly data)

Microsoft Excel
Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Selected Financial Data (US$ in millions)
Short-term borrowings 24 3 2 2 3 2 3 2 4 4 4 1 1
Current portion of long-term debt 1,350 1,350 1,350 1,350 600 600 600 1,100 500 500 500
Long-term debt, net of discount and issuance costs, excluding current portion 6,562 6,564 6,552 6,555 6,559 6,552 5,210 5,221 5,228 6,592 6,592 6,592 6,587 6,595 6,595 7,194 5,963 5,947 6,447 6,446 6,444
Total debt 6,586 6,567 6,554 6,557 6,562 7,904 6,563 6,573 6,578 6,592 6,592 7,196 7,191 7,199 7,696 7,695 6,463 6,447 6,447 6,446 6,444
Noncurrent operating lease liabilities 184 188 191 188 180 186 186 161 158 151 160 147 159 163 167 155 159 164 169 169 134
Total debt (including operating lease liability) 6,770 6,755 6,745 6,745 6,742 8,090 6,749 6,734 6,736 6,743 6,752 7,343 7,350 7,362 7,863 7,850 6,622 6,611 6,616 6,615 6,578
 
Total assets 14,348 14,286 14,106 13,749 13,754 14,925 13,674 13,770 13,860 13,900 13,705 14,069 13,796 13,609 13,725 13,069 11,528 11,545 11,272 10,986 10,883
Solvency Ratio
Debt to assets (including operating lease liability)1 0.47 0.47 0.48 0.49 0.49 0.54 0.49 0.49 0.49 0.49 0.49 0.52 0.53 0.54 0.57 0.60 0.57 0.57 0.59 0.60 0.60
Benchmarks
Debt to Assets (including Operating Lease Liability), Competitors2
Moderna Inc. 0.07 0.07 0.07 0.04 0.04 0.04 0.04 0.03 0.03 0.03 0.02 0.03 0.02 0.03 0.04 0.05 0.07 0.08 0.03 0.03 0.02

Based on: 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

1 Q1 2024 Calculation
Debt to assets (including operating lease liability) = Total debt (including operating lease liability) ÷ Total assets
= 6,770 ÷ 14,348 = 0.47

2 Click competitor name to see calculations.

Solvency ratio Description The company
Debt to assets (including operating lease liability) ratio A solvency ratio calculated as total debt (including operating lease liability) divided by total assets. Zoetis Inc. debt to assets ratio (including operating lease liability) improved from Q3 2023 to Q4 2023 and from Q4 2023 to Q1 2024.

Financial Leverage

Zoetis Inc., financial leverage calculation (quarterly data)

Microsoft Excel
Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Selected Financial Data (US$ in millions)
Total assets 14,348 14,286 14,106 13,749 13,754 14,925 13,674 13,770 13,860 13,900 13,705 14,069 13,796 13,609 13,725 13,069 11,528 11,545 11,272 10,986 10,883
Total Zoetis Inc. equity 5,058 4,997 5,078 4,625 4,494 4,405 4,663 4,580 4,658 4,543 4,679 4,350 4,089 3,769 3,602 2,982 2,753 2,708 2,678 2,411 2,317
Solvency Ratio
Financial leverage1 2.84 2.86 2.78 2.97 3.06 3.39 2.93 3.01 2.98 3.06 2.93 3.23 3.37 3.61 3.81 4.38 4.19 4.26 4.21 4.56 4.70
Benchmarks
Financial Leverage, Competitors2
AbbVie Inc. 18.59 13.00 11.26 10.52 10.14 8.04 8.84 9.77 8.80 9.51 10.99 11.77 10.98 11.51 9.80 10.17
Amgen Inc. 18.51 15.59 11.83 13.31 16.59 17.79 17.44 24.51 64.62 9.13 7.91 7.25 6.70 6.69 5.90 6.10 6.50 6.17 5.45 5.50 5.91
Bristol-Myers Squibb Co. 6.01 3.23 3.15 2.92 2.96 3.12 3.01 3.08 3.26 3.04 2.98 3.01 2.99 3.13 2.50 2.61 2.59 2.52 3.25 3.44 2.29
Danaher Corp. 1.56 1.58 1.67 1.64 1.65 1.68 1.72 1.76 1.80 1.84 1.90 1.82 1.87 1.92 1.92 1.97 2.22 2.05 1.89 1.66 1.64
Eli Lilly & Co. 4.99 5.94 5.16 4.95 4.75 4.65 4.71 5.51 5.03 5.44 6.21 7.42 6.79 8.27 9.10 10.25 13.35 15.07 11.20 13.91 15.32
Gilead Sciences Inc. 3.21 2.72 2.80 2.95 2.95 2.97 2.97 3.11 3.17 3.23 3.13 3.45 3.56 3.76 3.49 3.10 2.71 2.74 2.87 2.79 2.86
Johnson & Johnson 2.46 2.44 2.33 2.55 2.77 2.44 2.35 2.33 2.39 2.46 2.55 2.54 2.62 2.76 2.65 2.51 2.53 2.65 2.67 2.55 2.54
Merck & Co. Inc. 2.62 2.84 2.59 2.70 2.30 2.37 2.41 2.48 2.61 2.77 2.61 2.72 3.37 3.62 3.08 3.28 3.24 3.26 3.10 3.04 2.99
Moderna Inc. 1.31 1.33 1.45 1.29 1.28 1.35 1.45 1.45 1.62 1.74 2.07 2.41 3.31 2.86 1.69 1.18 1.26 1.35 1.27 1.26 1.25
Pfizer Inc. 2.40 2.54 2.22 2.22 1.94 2.06 2.10 2.24 2.23 2.35 2.37 2.43 2.31 2.44 2.74 2.77 2.56 2.65 2.62 2.62 2.64
Regeneron Pharmaceuticals Inc. 1.27 1.27 1.29 1.28 1.28 1.29 1.29 1.32 1.32 1.36 1.37 1.42 1.48 1.56 1.59 1.59 1.30 1.34 1.33 1.35 1.36
Thermo Fisher Scientific Inc. 2.13 2.11 2.14 2.15 2.24 2.21 2.08 2.14 2.26 2.33 1.90 1.84 1.88 2.00 2.01 2.06 2.05 1.97 1.93 2.02 2.01

Based on: 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

1 Q1 2024 Calculation
Financial leverage = Total assets ÷ Total Zoetis Inc. equity
= 14,348 ÷ 5,058 = 2.84

2 Click competitor name to see calculations.

Solvency ratio Description The company
Financial leverage ratio A solvency ratio calculated as total assets divided by total shareholders’ equity. Zoetis Inc. financial leverage ratio increased from Q3 2023 to Q4 2023 but then slightly decreased from Q4 2023 to Q1 2024.

Interest Coverage

Zoetis Inc., interest coverage calculation (quarterly data)

Microsoft Excel
Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Selected Financial Data (US$ in millions)
Net income attributable to Zoetis Inc. 599 525 596 671 552 461 529 529 595 414 552 512 559 359 479 377 423 384 433 371 312
Add: Net income attributable to noncontrolling interest (2) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1)
Add: Income tax expense 148 127 121 202 146 132 139 141 133 93 107 125 129 62 118 106 74 53 95 84 69
Add: Interest expense, net of capitalized interest 58 59 59 58 63 62 53 53 53 54 56 57 57 58 62 58 53 56 56 55 56
Earnings before interest and tax (EBIT) 805 709 776 930 760 654 720 723 780 560 715 693 744 478 659 540 550 493 584 510 437
Solvency Ratio
Interest coverage1 13.76 13.28 12.89 12.98 12.37 13.02 13.07 12.86 12.49 12.11 11.54 11.00 10.30 9.64 9.79 9.72 9.71 9.08
Benchmarks
Interest Coverage, Competitors2
Amgen Inc. 2.38 3.73 4.54 5.43 6.51 6.22 6.83 6.97 6.40 6.60 6.46 6.48 7.64 7.44 7.62 7.62 7.85 8.09
Danaher Corp. 17.81 18.64 23.66 29.65 35.60 40.30 41.32 35.26 33.54 32.92 28.74 25.87 21.54 17.35 16.90 20.00 25.33 31.44
Gilead Sciences Inc. 2.11 8.27 8.88 9.03 8.84 7.22 5.80 6.73 6.97 9.27 10.06 7.61 2.93 2.70 2.83 0.41 5.90 6.19
Johnson & Johnson 29.06 20.51 19.09 23.89 31.49 79.71 141.63 160.27 164.15 125.46 94.27 87.06 73.87 83.07 96.82 81.36 81.56 55.49
Regeneron Pharmaceuticals Inc. 57.85 58.52 61.70 69.61 73.97 82.80 108.62 116.35 163.24 163.75 139.74 104.12 68.20 67.97 72.22 108.12 90.22 81.43
Thermo Fisher Scientific Inc. 5.53 5.54 5.98 6.64 8.28 11.56 13.59 15.70 16.73 17.49 19.94 19.52 17.58 14.07 10.78 7.93 7.66 7.02

Based on: 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

1 Q1 2024 Calculation
Interest coverage = (EBITQ1 2024 + EBITQ4 2023 + EBITQ3 2023 + EBITQ2 2023) ÷ (Interest expenseQ1 2024 + Interest expenseQ4 2023 + Interest expenseQ3 2023 + Interest expenseQ2 2023)
= (805 + 709 + 776 + 930) ÷ (58 + 59 + 59 + 58) = 13.76

2 Click competitor name to see calculations.

Solvency ratio Description The company
Interest coverage ratio A solvency ratio calculated as EBIT divided by interest payments. Zoetis Inc. interest coverage ratio improved from Q3 2023 to Q4 2023 and from Q4 2023 to Q1 2024.